Bin Jiang

US Patent:

20200024257, Jan 23, 2020

Filed:

Nov 8, 2017

Appl. No.:

16/348195

Inventors:

- Princeton NJ, US
Bin Jiang - Bryn Mawr PA, US
Zhonghui LU - King of Prussia PA, US
Arun Kumar Gupta - Bangalore Karnataka, IN
Ananta Karmakar - Bangalore Karnataka, IN

International Classification:

C07D 401/14
C07D 207/16
C07D 207/06
C07D 207/12
C07D 401/06
C07D 403/04
C07D 413/06
C07D 405/12

Abstract:

There are described RORγ modulators of the formula (I),or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

US Patent:

20180221344, Aug 9, 2018

Filed:

Aug 2, 2016

Appl. No.:

15/749611

Inventors:

- Princeton NJ, US
Bin Jiang - Bryn Mawr PA, US
Jingwu Duan - Yardley PA, US

International Classification:

A61K 31/4184
A61K 31/4188
A61P 37/02

Abstract:

Disclosed are compounds of Formula (I) or a salt thereof, wherein: Ring A is 3- to 6-membered carbocyclic or heterocyclic ring; X is CRor N; Y is —(CRR)—; Z is —(CRR)—; and q, R, R, R, R, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as modulators of TNFα, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

US Patent:

20160326103, Nov 10, 2016

Filed:

Jan 5, 2015

Appl. No.:

15/109741

Inventors:

- Princeton NJ, US
Bin Jiang - Bryn Mawr PA, US
Zhonghui Lu - King of Prussia PA, US
Ananta Karmakar - Bangalore, IN
Arun Kumar Gupta - Bangalore, IN
Carolyn A. Weigelt - Langhorne PA, US

International Classification:

C07C 317/14
C07C 317/32
C07D 303/34
C07D 317/44
C07D 295/185
C07C 317/44
C07C 317/50
C07D 309/14
C07D 231/12
C07D 213/30
C07D 213/85
C07D 239/38
C07D 261/08
C07D 319/20
C07D 213/75
C07D 213/40
C07D 211/62
C07D 295/108
C07D 295/155
C07D 205/04
C07D 471/04
C07D 471/10
C07D 401/04
C07D 237/08
C07C 317/22

Abstract:

Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

US Patent:

20160326104, Nov 10, 2016

Filed:

Jan 5, 2015

Appl. No.:

15/109733

Inventors:

- Princeton NJ, US
Bin JIANG - Bryn Mawr PA, US
Ananta KARMAKAR - Bangalore, IN
Arun Kumar GUPTA - Bangalore, IN
Zhonghui LU - King of Prussia PA, US
Carolyn A. WEIGELT - Langhorne PA, US

International Classification:

C07C 317/20
C07C 317/24
C07D 213/81
C07D 295/096
C07C 317/30
C07D 231/54
C07D 277/82
C07D 213/30
C07D 213/75
C07D 205/04
C07D 207/277
C07D 211/62
C07D 211/78
C07D 309/08
C07D 213/56
C07D 231/14
C07D 295/195
C07D 207/27
C07D 237/24
C07D 239/28
C07D 241/24
C07D 401/06
C07D 405/04
C07D 401/04
C07D 295/16
C07D 471/04
C07D 249/06
C07D 403/04
C07D 401/12
C07D 237/22
C07D 237/08
C07D 211/46
C07D 335/02
C07C 317/46

Abstract:

Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

US Patent:

20160326108, Nov 10, 2016

Filed:

Jan 5, 2015

Appl. No.:

15/109719

Inventors:

- Princeton NJ, US
Bin JIANG - Bryn Mawr PA, US
Zhonghui LU - King of Prussia PA, US

International Classification:

C07D 207/12
C07D 403/04
C07D 405/06
C07D 403/06
C07D 401/14
C07D 417/06
C07D 413/06
C07D 417/14
C07D 403/12
C07D 405/12
C07D 413/12
C07D 401/12
C07D 493/08
C07D 409/12
C07D 493/04
C07D 471/08
C07D 401/06

Abstract:

Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

US Patent:

20160326115, Nov 10, 2016

Filed:

Jan 5, 2015

Appl. No.:

15/109727

Inventors:

- Princeton NJ, US
Bin Jiang - Bryn Mawr PA, US
Ananta Karmakar - Bangalore, IN
Arun Kumar Gupta - Bangalore, IN
Zhonghui Lu - King of Prussia PA, US

International Classification:

C07D 211/54
C07D 211/96
C07D 405/06
C07D 309/08
C07D 401/06

Abstract:

Described are RORγ modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.